DNB Fund Women's Health
DNB Fund Women's Health is a thematic equity fund that invests in companies with documented relevance to women's health.
DNB Fund Women's Health
DNB Fund Women's Health provides exposure to pure women's health companies and companies where women's health is an important growth driver.
The fund has a broad approach and invests across sectors, including healthcare, technology and consumer-related companies. The objective is to invest in companies that benefit from growth in women's health.
Minimum purchase amount is NOK 100.
Costs for DNB Fund Women's Health
- Annual cost: 1.15 %
- Ongoing charge: 0.85%
- Platform fee:0.30%
Price example: For an amount of NOK 100,000 invested, the platform fee will be NOK 300and ongoing charges will be NOK 850 over the course of one year. Total NOK 1,150NOK per year.
Any transaction costs to the manager are not included in the cost overview. These are stated under cost details on the summary page before you purchase the fund.
The fund's investment focus
Women's health represents a market with significant and long-term growth potential. Increased awareness, technological advances, improved diagnostics and demographic changes are helping to drive development forward.
The fund is based on a structured investment framework that identifies companies within three key areas: treatment, prevention and quality of life.
The fund suits investors who want exposure to a broad universe of companies that can benefit from the structural growth in women's health. The ambition is to generate an attractive long-term rate of return. The fund follows DNB's Group instructions for Responsible Investments.
Women's health
The objective is to invest in companies that benefit from growth in women's health, regardless of sector.
Three investment pillars
- Treatment: Pharmaceuticals, biotechnology and medical solutions (e.g. cancer, reproductive health, autoimmune diseases).
- Prevention: Diagnostics, screening, digital health and wearables.
- Quality of life: Products and services that improve health and function in everyday life.
Portfolio manager
Anesa Mulabecirovic Sahnoun
Portfolio manager Anesa Mulabecirovic Sahnoun is a medical doctor with a PhD in medicine and an MBA from the Norwegian School of Economics. She has extensive experience from clinical work, professional development and the healthcare sector, and has held several leading positions in Norwegian and European professional communities.
Since 2021, she has been part of the healthcare team at DNB Asset Management, where she analyses and follows global companies within pharmaceuticals, biotechnology, diagnostics and health technology.
Historical returns are no guarantee of future returns. Future returns will depend, among other things, on market developments, the skill of the Portfolio Manager, the mutual fund's risk, and the management costs. Returns may be negative as a result of mark-to-market losses.